Publication date: Nov 12, 2024
To explore the value of computed tomography based radiomics in the differential diagnosis of drug-sensitive and drug-resistant pulmonary tuberculosis. The clinical and computed tomography image data of 177 patients who were diagnosed with pulmonary tuberculosis through sputum culture and completed drug-susceptibility testing from April 2018 to December 2020 at the Second Hospital of Nanjing were retrospectively analyzed. Patients with drug-resistant pulmonary tuberculosis (n = 78) and drug-sensitive pulmonary tuberculosis (n = 99) were randomly divided into a training set (n = 124) and a validation set (n = 53) at a ratio of 7:3. Regions of interest were drawn to delineate the lesions and radiomics features were extracted from non-contrast computed tomography images. A radiomics signature based on the valuable radiomics features was constructed and a radiomics score was calculated. Demographic data, clinical symptoms, laboratory results and computed tomography imaging characteristics were evaluated to establish a clinical model. Combined with the Rad-score and clinical factors, a radiomics-clinical model nomogram was constructed. Thirteen features were used to construct the radiomics signature. The radiomics signature showed good discrimination in the training set (area under the curve (AUC), 0. 891; 95% confidence interval (CI), 0. 832-0. 951) and the validation set (AUC, 0. 803; 95% CI, 0. 674-0. 932). In the clinical model, the AUC of the training set was 0. 780(95% CI, 0. 700-0. 859), while the AUC of the validation set was 0. 692 (95% CI, 0. 546-0. 839). The radiomics-clinical model showed good calibration and discrimination in the training set (AUC, 0. 932;95% CI, 0. 888-0. 977) and the validation set (AUC, 0. 841; 95% CI, 0. 719-0. 962). Simple radiomics signature is of great value in differentiating drug-sensitive and drug-resistant pulmonary tuberculosis patients. The radiomics-clinical model nomogram showed good predictive, which may help clinicians formulate precise treatments.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | pulmonary tuberculosis |
| disease | IDO | susceptibility |
| pathway | REACTOME | Reproduction |
| drug | DRUGBANK | Coenzyme M |
| disease | IDO | drug susceptibility |
| disease | MESH | Tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | MESH | infection |
| drug | DRUGBANK | Rifampicin |
| drug | DRUGBANK | Trestolone |
| drug | DRUGBANK | Ademetionine |
| disease | MESH | adenocarcinoma |
| disease | MESH | tuberculous pleurisy |
| disease | MESH | lung cancer |
| disease | MESH | lung diseases |
| disease | MESH | AIDS |
| disease | IDO | history |
| disease | IDO | blood |
| disease | IDO | bacteria |
| disease | MESH | breath holding |
| disease | MESH | emphysema |
| disease | MESH | atelectasis |
| disease | MESH | bronchiectasis |
| disease | MESH | fibrosis |
| disease | MESH | pleural effusion |
| disease | MESH | Tuberculosis Multidrug-Resistant |